Fig. 5.

Combination treatment with JK184 and B7-H3 CAR T cells showed superior tumor control in MDA-MB-231 and HCT116 xenograft mouse models. A Treatment scheme used in the MDA-MB-231-FFluc and HCT116-FFluc xenograft models. B Kaplan-Meier analysis of MDA-MB-231-FFluc tumor-bearing mice in each group (n = 5 per group). C and E On days 7, 14, and 21 after tumor injection, representative bioluminescence images of MDA-MB-231-FFluc or HCT116-FFluc cell growth are shown. D and F Tumor growth was monitored by bioluminescence, and the average tumor radiance (p/s/cm²/sr) was calculated in the two xenograft models. G Overall survival analysis of HCT116-FFluc tumor-bearing mice in each group (n = 5 per group). H Mice-bearing tumors derived from MDA-MB-231-FFluc cells were sacrificed on day 20 after inoculation. Paraffin tumor sections were stained with CD3 and cleaved caspase3. Scale bar: 50 μm. T tests were used to determine statistical significance of the differences in D and F. *P < 0.05, **P < 0.01, ***P < 0.001 and ****P < 0.0001, ns not significant. P values for B and G were determined by the log-rank test, two-tailed, *P < 0.05, **P < 0.01